Kornimate/medical-research-clean huggingface dataset:
neuroaid safe treatment registry

Conditions: Brain Injury; NeuroAiD Use

Summary: the nest registry is a pro-active industry-academic collaboration to assess the use and safety of neuroaid in the real world setting. an online entry system was set up to allow easy data entry and retrieval of clinical information.

the nest registry is designed as a product registry that would provide information on the use and safety of neuroaid in clinical practice. an online nest registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional, and cognitive state, compliance, concomitant medications and side effects if any, among patients on neuroaid. participation is voluntary. data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialization of neuroaid) and during subsequent visits. the follow up visits are timed with clinical appointments. anonymized data will be extracted and collectively analyzed. initial target sample size for the registry is 2000.

Eligibility criteria:
inclusion criteria: * male or female * any age * taking, or has been prescribed neuroaid for any duration as judged by the physician and/or the participant * agrees to be included in the registry and allows retrieval and analysis of data in accordance with local requirements exclusion criteria: * unwillingness to participate * contraindication to neuroaid
vaginal cuff closure time using unidirectional barbed suture in robotic hysterectomy

Conditions: Disease (or Disorder); Gynecological

Summary: this study is designed to determine if using the v-loc wound closure system expedites operative time in robotic hysterectomy.

currently both traditional continuous smooth suture and unidirectional barbed suture techniques are standard of care in robotic hysterectomy and the decision of which to use is at the discretion of the surgeon. by using unidirectional barbed suture in which no knot tying is required, wound closure time may be decreased resulting in decreased operative time. this study was created to compare vaginal cuff closure times using these two techniques.

Eligibility criteria:
inclusion criteria: * women being scheduled to have a robotic hysterectomy for benign or malignant disease by the west clinic gynecology-oncology physicians * females age 18+ exclusion criteria: * patients receiving ongoing radiation therapy to the pelvis

Keywords: vaginal cuff robotic hysterectomy vloc v-loc vicryl unidirectional barbed suture
diagnosis of pcl with eus-fna and cross-sectional imaging - a report of accuracy

Conditions: Pancreatic Cyst; Pancreatic Neuroendocrine Carcinoma; Pancreatic Pseudocyst; Pancreatic Serous Cystadenoma; Pancreatic Mucinous Cystadenoma; Pancreatic Cystadenocarcinoma; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Solid Pseudopapillary Tumor of the Pancreas

Summary: pancreatic cystic lesions (pcls) comprise of a heterogeneous group of entities that are benign, premalignant or malignant. with increased use of modern imaging techniques in recent years, incidentally discovered pcl have become much more common. however, imaging modalities for characterising pcl is a known clinical uncertainty since imaging is capable of detecting these lesions but may often not be able to distinguish malignant from benign lesions. incorrect assessment of pcl can lead to fatal consequences because a malignant lesion may not be treated and a benign may be unnecessarily resected. the aim of this study was to assess the performance of endoscopic ultrasound with fine-needle aspiration (eus-fna) in the diagnosis of pancreatic cystic lesions compared to cross-sectional imaging modalities (ct/mri). our hypothesis is that eus-fna has a higher accuracy for diagnosing pcls compared with cross-sectional imaging.


Eligibility criteria:
inclusion criteria: patients with suspected pcls according to radiology undergoing evaluation with eus-fna at a tertiarry endoscopy center from february 2007 until march 2017, who underwent pancreas resection oral and written consent of patients examined exclusion criteria: none

Keywords: endoscopic ultrasound radiology accuracy pancreatic cyst pancreatic cystadenocarcinoma pancreatic mucinous cystadenoma pancreatic intraductal papillary-mucinous neoplasm pancreatic serous cystadenoma pancreatic pseudocyst pancreatic neuroendocrine tumor solid pseudopapillary tumor of the pancreas
determination of the left paratrachéal force required to occlude the esophageal entrance

Conditions: Oesophageal Reflux

Summary: determine the force required to occlude the esophagus with a left paratracheal pressure


Eligibility criteria:
inclusion criteria: * physical status score 1 or 2 * no contre indication to left paratracheal pressure exclusion criteria: * obese patients * physical status score 3, 4 or 5 * contre indication to left paratracheal pressure
immunogenicity and safety of v419 (pr51) in combination with mcc in infants and toddlers (v419-011)

Conditions: Neisseria Meningitidis; Bacterial Infections; Virus Diseases

Summary: the primary objectives of this study are to evaluate the immunogenicity and safety of concomitant administration of v419 (pr51) with 2 types of meningococcal serogroup c conjugate (mcc) vaccines to healthy infants at 3 and 4 months of age in terms of antibody seroprotection rate (spr) to mcc. participants also received a haemophilus influenza type b (hib)-mcc vaccination at 12 months of age. it was hypothesized that the spr to mcc at 1 month post-dose 2 of either tetanus toxoid conjugated meningo c (mcc-tt) or crm197 conjugated meningo c (mcc-crm) vaccines would be acceptable when administered concomitantly with v419.


Eligibility criteria:
inclusion criteria: * healthy infant 46 to 74 days of age (both inclusive) * parent(s)/legal representative able to comply will the study procedures exclusion criteria: * is participating in a study with an investigational compound or device since birth * has a history of congenital or acquired immunodeficiency * has a history of leukemia, lymphoma, malignant melanoma or myeloproliferative disorder * has a chronic illness that could interfere with study conduct or completion * has hypersensitivity to any of the vaccines components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines or contraindication to any of the study vaccines * has a history, or mother has a history, of hepatitis b virus surface antigen (hbsag) seropositivity * has a coagulation disorder that contraindicate intramuscular injection * has a history of vaccination with a hepatitis b, haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acellular or whole-cell), poliovirus, pneumococcal conjugate or polysaccharide, meningococcal serogroup c conjugate, measles, mumps, or rubella containing vaccine(s) * has a history of hepatitis b, haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, invasive pneumococcal, meningococcal serogroup c, measles, mumps or rubella infection * has received immune globulin, blood or blood-derived products, immunosuppressive agents systemic corticosteroids since birth * has received vaccination with an inactivated (except influenza vaccine) or conjugated or live vaccine in the last 30 days or vaccination with an inactivated influenza vaccine in the last 14 days * has received antipyretic, analgesic and non-steroidal anti-inflammatory medications in the last 48 hours * has a febrile illness or body temperature ≥38.0°c in the last 24 hours
open-label trial of sulforaphane in premutation carriers with fxtas

Conditions: Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)

Summary: fxtas is a rare genetic progressive neurodegenerative disorder, linked to a trinucleotide repeat expansion in the fmr1 gene. fxtas is characterized by tremor and ataxia in addition to atrophy and white matter disease in the central nervous system (cns). in addition to the major clinical observations of intention tremor and gait dysfunction, minor symptoms of parkinsonism, neuropathy, and cognitive decline also significantly impact individuals with fxtas. the dietary supplement being tested in this study is called sulforaphane. it is found in broccoli and similar cruciferous vegetables and may cause some gas and discomfort. this is not a study looking at clinical efficacy but instead a study of molecular outcome measures. investigators want to get more information about how sulforaphane affects specific biomolecular markers captured in blood. in this study, participants will be taking an increasing amount of the sulphoraphane supplement pills (238mg/tablet), starting at 1 and increasing to 6, every morning at breakfast for 6 months. in addition, there will be a total of 3 visits (initial, 3-month and 6-month) to the mind institute where participants will be evaluated. at each visit (3 total) participants will undergo a battery of medical and neurologic exams which make take 2-3 days to complete each time. participants and/or their caregivers will also be asked to fill out questionnaires/surveys. at the initial visit and at 6 months, we will collect blood for analysis. two mri scans will be done, also at the initial visit and at 6 months.


Eligibility criteria:
inclusion criteria: * diagnosis of fxtas * presence of a fmr1 premutation (55 to 200 cgg repeats) exclusion criteria: * individuals with severe renal failure (gfr is \<60 ml/min/1.73 m\^2) * significant and current reported substance abuse * individuals with substance use disorder (meets 6 or more symptoms of substance use disorder criteria) * any subject on hospice or on home oxygen * individuals who are pregnant

Keywords: sulforaphane
underwater resection of non-pedunculated colorectal lesions

Conditions: Colorectal Neoplasms

Summary: the aim of this study is to compare the efficacy of underwater resection (polypectomy) versus conventional polypectomy techniques for small and large colorectal lesions identified during colonoscopy.

conventional endoscopic resection of small and large (≥1cm) colorectal lesions is well established and performed with the colon fully distended with gas. conventional polypectomy is effective, but the rate of incomplete resection is approximately 10%. incomplete eradication of precancerous lesions contributes to interval colorectal cancer; therefore, alternative techniques for resection that safely and effectively increase the rate of complete resection are important. underwater resection (ur) of benign colorectal lesions is a novel technique that utilizes the advantages of water aided endoscopic methods and may decrease the incomplete resection rate of small and large non-pedunculated lesions. the investigators propose the hypothesis that small (6-9mm) and large (≥1cm) non-pedunculated neoplastic colorectal lesions resected by ur (partially distended, water filled lumen without submucosal fluid injection), will significantly decrease the incomplete resection rate (irr) compared to conventional polypectomy performed in a gas distended lumen. small (6-9mm) and large (≥1cm) non-pedunculated benign neoplastic colorectal lesions identified during screening, surveillance, diagnostic or therapeutic colonoscopy will be randomized to conventional polypectomy (in a gas distended lumen with or without submucosal fluid injection) versus ur (partially distended, water filled lumen without submucosal injection) at the patient level. small (6-9mm) lesions will be removed with a 9mm firm, thin wire cold snare and large (≥1cm) lesions will be removed by snare electrocautery. efforts to remove lesions en bloc with a small rim of normal mucosa will be made, although some larger lesions (≥2cm) may require piecemeal resection. submucosal fluid injection with a solution may be used with conventional techniques for large and/or flat lesions. post-polypectomy incomplete resection rates will be assessed from 4 quadrant biopsies obtained around the resection site immediately post-resection.

Eligibility criteria:
inclusion criteria: * adult (≥18 years old) male and female patients. * scheduled for outpatient colonoscopy. * patient able to provide informed consent. * benign, small (6-9mm) and large (≥1cm) non-pedunculated colorectal lesions. exclusion criteria: * diminutive (≤5mm) and pedunculated polyps. * lesions suspected of harboring deep submucosal invasion. * patients who decline to participate or are unable to provide informed consent.

Keywords: colonoscopy polypectomy
blackberry flavonoid absorption and effects on intestinal bacteria

Conditions: Metabolic Syndrome

Summary: intestinal bacteria can metabolize unabsorbed polyphenols (plant compounds) to produce smaller molecules which may impact health. in addition, evidence suggests that this process may be affected by body fatness. this study aims to investigate absorption of blackberry polyphenols, their impact on intestinal bacteria, polyphenol metabolites formed by intestinal bacteria, and how these processes differ for obese and lean individuals. it is hypothesized that polyphenol absorption and metabolism will differ between obese and lean individuals and that differences in intestinal microbiota may play a role.


Eligibility criteria:
inclusion criteria: * 25-75 years old exclusion criteria: * use of blood-thinning medications such as coumadin (warfarin), dicumarol (dicumarol), or miradon (anisindione) * presence of any gastrointestinal disease, metabolic disease, or malabsorption syndromes that may interfere with the study goals * have been pregnant during the previous 12 months, are currently pregnant or lactating, or plan to become pregnant during the study * type 2 diabetes requiring the use of oral antidiabetic agents or insulin * fasting triglycerides greater than 300 mg/dl * fasting glucose greater than 126 mg/dl * history of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets) * use of prescription or over-the-counter antiobesity medications or supplements (e.g., phenylpropanolamine, ephedrine, caffeine) during and for at least 6 months prior to the start of the study or a history of a surgical intervention for obesity * active cardiovascular disease (such as a heart attack or procedure within the past three months or participation in a cardiac rehabilitation program within the last three months, stroke, or history/treatment for transient ischemic attacks in the past three months, or documented history of pulmonary embolus in the past six months). * use of any tobacco products in past 3 months * unwillingness to abstain from herbal supplements for two weeks prior to the study and during the study * known (self-reported) allergy or adverse reaction to blackberries or other study foods * unable or unwilling to give informed consent or communicate with study staff * self-report of alcohol or substance abuse within the past twelve months and/or current acute treatment or rehabilitation program for these problems (long-term participation in alcoholics anonymous is not an exclusion) * other medical, psychiatric, or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocol
icbt for anxiety and depressive symptoms in brazilian young adults

Conditions: Anxiety Symptoms; Depressive Symptoms

Summary: this study aims to investigate the effects of a selfguided internet-based cognitive behavioral therapy (icbt) program on depressive and anxiety symptoms in young brazilian adults. treatment group will be compared to a waiting list control group. participants will be recruited in brazil with a nationwide recruitment.

this is a randomized controlled trial carried out to evaluate the effects of an internet-based cognitive behavioral program for depressive and anxiety symptoms in young brazilians adults. the program consists of 8 weeks of treatment and is carried out through an online platform. during treatment, participants have the support of a therapist who can be reached on demand via the platform\&#39;s text messaging channel. the program was adapted to brazilian culture from previous work.

Eligibility criteria:
inclusion criteria: * (1) age between 18 and 24 years old; (2) have a device with internet access that allows access to the platform; (3) speak and read brazilian portuguese. exclusion criteria: * (1) having a severe psychiatric diagnosis such as bipolar disorder and schizophrenia; (2) having severe suicidal ideation or reported suicidal intent; (3) reporting substance abuse; (4) being in an ongoing psychological and/or psychiatric treatment; (5) changing psychiatric medication less than 3 months before the treatment starts; (6) scoring extremely severe on all three subscales of dass-21 (28+ for depression, 20+ for anxiety and 34+ for stress.

Keywords: internet-delivered interventions anxiety depression young adults cognitive-behavioral therapy
prospective single centre observational study to compare the diagnostic yield of different modalities of liver biopsy

Conditions: Liver Diseases; Liver Fibrosis

Summary: the goal of this study is to learn about endoscopic ultrasound(eus) guided liver biopsy and how this compares to traditional methods of obtaining liver biopsy samples, in patients with liver disease. the main questions it aims to answer are: 1. is eus liver biopsy equally as good as other types of techniques 2. are there any advantages to using the eus technique to obtain liver biopsies researchers will compare data from patients who have had a liver biopsy with a traditional technique with those who have undergone eus-guided biopsy.

introduction: the rising incidence of liver disease (ld) has led to an increased demand on services for accurate and prompt diagnosis and staging, to facilitate treatments and early interventions. while non-invasive diagnostic tests (e.g. transient elastography, elf biomarkers) are the standard of care to stratify fibrosis burden, there are still cases that require a liver biopsy (lb) for assessment of fibrosis and aetiology of disease. traditional methods such as percutaneous lb (plb) and transjugular lb (tjlb) are well established, however there is a recognised burden on the services, translating to prolonged waiting times and delays in diagnosis. endoscopic ultrasound-guided liver biopsy (eus-lb) is emerging as a novel, minimally invasive way of not only securing a tissue sample, but also providing an in-depth assessment of other parameters such as portal pressure gradient (ppg), shearwave measurement (swm) and varices assessment. the aim of this study was to test the diagnostic adequacy, fibrosis staging, length of stay post procedure and complication rates following the above modalities of liver biopsy. methods: this is a single centre prospective observational study to assess the diagnostic accuracy of liver biopsy through different modalities. data will be as collected prospectively from all adult patients patients undergoing any form of lb in a single tertiary hospital for 12 months:september 2022 to september 2023. information was collected will be on demographics, biopsy indication, length of core, length of stay (los), complications and diagnostic yield. primary aim: to assess the diagnostic yield of liver biopsy through eus-lb, trans-jugular liver biopsy and percutaneous ultrasound guided liver biopsy. secondary aim; 1. technical success rate, 2. length of the cores obtained 3. number of portal tracts 4. accuracy of shear wave measurement compared to liver biopsy 5. complications rate 6. length of stay dissemination plan: the results of the study will be disseminated through presentation at national/ international meetings and publishing in peer reviewed journals.

Eligibility criteria:
inclusion criteria: * 18 years or older * underwent liver biopsy either through eus, percutaneous or transjugular route exclusion criteria: - under 18 years of age

Keywords: eus endoscopic ultrasound liver biopsy percutaneous liver biopsy trans-jugular liver biopsy eus shear wave measurement
effect of testofen on erectile function in an adult male population

Conditions: Erectile Dysfunction

Summary: this is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect testofen may have on improving erectile function, sexual function, and quality of life.


Eligibility criteria:
inclusion criteria: * healthy male adults aged 40-75 years * currently in a sexual relationship * males with reduced erectile function (score of \<25 on iief) * bmi ≤ 35 * able to provide informed consent * agree not to change current diet and exercise program while enrolled in this trial * agree not to undertake another clinical trial while enrolled in this trial exclusion criteria: * history of prostate surgery and/or trauma * receiving/prescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories * receiving/prescribed treatment to increase/decrease testosterone levels e.g. androgens/anti androgens * receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels * unstable or serious illness (e.g. serious mood disorders, neurological disorders such as ms, kidney disease, liver disease, heart conditions, diabetes, hormone production disorders)\* * all current malignancies (excluding bcc) or chemotherapy and/or radiotherapy treatment for malignancy within the previous 2 years * receiving/prescribed \[e.g., coumadin or marevan (warfarin), heparin, dalteparin, enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of vena cava filters) * active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse * chronic past and/or current alcohol use (\>14 alcoholic drinks week) * allergic to any of the ingredients in the active or placebo formula * any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * participants who have participated in any other related clinical study during the past 1 month a any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone). \*an unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. a serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.